TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Mesoblast ( (MESO) ) has issued an update.
On July 14, 2025, Mesoblast Limited announced several filings with the Australian Securities Exchange, including the cessation of 483,254 unquoted equity securities due to unmet conditions as of June 30, 2025. These changes reflect adjustments in the company’s issued capital, impacting its market capitalization and potentially influencing stakeholder perceptions.
The most recent analyst rating on (MESO) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Mesoblast stock, see the MESO Stock Forecast page.
Spark’s Take on MESO Stock
According to Spark, TipRanks’ AI Analyst, MESO is a Neutral.
The overall score is primarily impacted by Mesoblast’s poor financial performance, characterized by declining revenues and negative cash flows. Technical analysis also reflects a bearish outlook. Additionally, the valuation is unfavorable due to negative earnings and no dividend yield.
To see Spark’s full report on MESO stock, click here.
More about Mesoblast
Mesoblast Limited is an Australian company operating in the biotechnology industry, primarily focusing on the development and commercialization of innovative cellular medicines. The company is known for its work in regenerative medicine and stem cell therapy, targeting conditions such as heart failure and chronic low back pain.
Average Trading Volume: 205,157
Technical Sentiment Signal: Sell
Current Market Cap: $1.38B
See more data about MESO stock on TipRanks’ Stock Analysis page.